Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Pevonedistat in Adult East Asian Participants
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)
- Status
- UNKNOWN
- Phase
- NA
Tipifarnib in Subjects With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE2
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
Prophylactic Application of Donor-derived TCM After Allogeneic HSCT
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Investigation of the Genetics of Hematologic Diseases
- Status
- RECRUITING
- Phase
- N/A
PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.
- Status
- COMPLETED
- Phase
- NA
Allo HSCT Using RIC for Hematological Diseases
- Status
- COMPLETED
- Phase
- PHASE2
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE3
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
- Status
- TERMINATED
- Phase
- PHASE2
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- NA
Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
- Status
- UNKNOWN
- Phase
- PHASE1
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2